Citations

Clear

9383 citation(s) found for "Thomas, PS".

Abstract CT225: Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial
Nauseef, Jones T. , Thomas, Charlene , Sun, Michael, Jacobs, Nicole , Rüder, S, Fernandez, Escarleth, Davidson, Zachary, Patel, Amie , Vallabhajosula, Shankar , Molina, Ana M. , Nanus, David M. , Castellanos, Sandra Huicochea , Bander, Neil H. , Jacobs, Nicole, Ricaurte‐Fajardo, Andres , Sartor, Oliver , Sternberg, Cora N , Osborne, Joseph R. , Perk, Timothy , Tagawa, Scott T.

Mayo Clinic

Cancer Research | April 5, 2024 | Volume: 84 | Issue: 7_Supplement | Pages: CT225-CT225

10.1158/1538-7445.am2024-ct225 Get It

Abstract Background: We have previously reported that 177Lu-PSMA-617 given as a single-cycle, dose-intense regimen for patients (pts) with pretreated mCRPC is efficacious even without selection by PSMA (ESMO 2021). Quantitative analyses of pre-treatment PSMA PET may allow for better patient selection and prediction of toxicities. Analyses of sequential PET images may also provide insights that may be associated with longer term outcomes. Our previous analysis of 13 patients demonstrated association of PSMA PET signal with overall survival (OS) and PSA responses, as well as trends with adverse events (Nauseef GU ASCO 2022). Here we present long-term follow up data and expanded imaging correlatives from our completed phase I/II study. MethodsEntry criteria: progressive mCRPC after at least one prior potent AR pathway inhibitor and prior chemotherapy (excepting men ineligible for or refusing of chemotherapy) with allowance for prior radionuclides (incl. Ra223 and PSMA-TRTs). Treatment was fractionated-dose (D1 and D15) 177Lu-PSMA-617 (7.4-22.2 GBq). TRAQinform IQ (AIQ Solutions) was used to identify, track, and quantify regions of interest suspicious of cancer (lesion-ROI) on PSMA PET/CT images and quantify uptake in normal organs outside of lesion-ROI. Measurements included SUVmean across all lesion-ROI, volume of lesion-ROI, and SUVtotal (sum of SUV in all lesion-ROI), as well as changes after treatment, including in PSMA-expressing healthy tissues. Associations with survival were tested via Cox proportional hazard models in univariate analyses and associations with adverse events (AEs) and PSA responses were via assessed via Wilcoxon rank sum tests. Results32 pts (of 50 total in the study between 1/2017-2/2021) had pre- and post-treatment imaging suitable TRAQinform IQ analysis and associated survival analyses. Baseline characteristics were similar to the entire study cohort. PSA response of 50% was observed in 21/32 (66%) of which 16 were confirmed. No imaging variable predicted PSA30 or PSA50, although an association was observed in pretreatment SUVmean and lesion-ROI volume reduction. No imaging variable was significantly associated with OS (e.g., pretx SUVmean HR 0.9, p=0.10, pretx Volume HR 1.00, p=0.052). Pretx SUVmean was associated with mPFS (HR 0.85, 95% CI 0.74, 0.98, p=0.023). Among select AEs, anemia was associated with non-lesion-ROI skeleton SUVtotal in pre- (p=0.027) and post-tx (p=0.007). Higher pre-treatment salivary gland uptake (SUVmean) was associated with more xerostomia (p=0.11). Fatigue was associated with a variety of variables including salivary SUVs (mean, max, and total) and post-tx bowel SUVmax (p=0.030). ConclusionsPre-treatment and pre- to post-treatment 68Ga-PSMA11-PET data analyzed may be associated with outcome. While a strength of this study is the prospective nature of patient enrollment and fixed imaging timepoints, our associations are limited by small sample size. Expansion of this analysis to larger datasets may improve our ability to predict treatment response and toxicity by body-wide PSMA detection. Citation Format: Jones Trevor Nauseef, Charlene Thomas, Michael Sun, Nicole Jacobs, Andrés Ricaurte Fajardo, Sam Ruder, Escarleth Fernandez, Zachary Davidson, Amie Patel, A. Oliver Sartor, Shankar Vallabhajosula, Ana Molina, Cora N. Sternberg, David M. Nanus, Sandra Huicochea Castellanos, Joseph Osborne, Neil H. Bander, Timothy Perk, Scott Tagawa. Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT225.
Abstract CT133: A phase 1b multicenter study of anti-TIM3 (S095018/Sym023) in combination with anti-PD1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer
Razak, Albiruni Ryan Abdul, Liao, Chih‐Yi , Raimbourg, Judith , Geromini, Julia, Harouki, Najah , Rodrigues, Christelle , Darcel, Pauline, Skartved, Niels Jørgen Østergaard, Hald, Rikke , Lopez-Ravnborg, Daleen, He, Peng , Ianopoulos, Xenophon, Askoxylakis, Vasileios , Davis, S. Lindsey , Ghiringhelli, François , Kim, Richard D. , Macarulla, Teresa , Moreno, Irene Gala , Rodon, Jordi , Marron, Thomas , Kaplon, Hélène , Lakhani, Nehal J. , Mahipal, Amit

Mayo Clinic

Cancer Research | April 5, 2024 | Volume: 84 | Issue: 7_Supplement | Pages: CT133-CT133

10.1158/1538-7445.am2024-ct133 Get It

Abstract Background: TIM3 is an inhibitory immunoreceptor linked to decreased activity of immune cells in the tumor microenvironment. S095018 is a human anti-TIM3 IgG2 antibody which blocks binding of phosphatidyl serine to TIM3 promoting the stimulation of T-cells, dendritic cells (DCs) and macrophages. Sym021 is a humanized IgG1 antibody that inhibits binding of PD-1 with its ligands PD-L1 and PD-L2. Preclinical data demonstrated that Sym021 combined with S095018 results in enhanced immunostimulatory antitumor activity. Methods: S095018 in combination with Sym021 was tested in patients with advanced/metastatic biliary tract cancer whose disease progressed under treatment with at least one line of systemic therapy and who had not received prior treatment with PD-1/-L1 inhibitors (NCT04641871). The dose/schedule of Sym021 and S095018 was 3mg/kg IV Q2W and 10mg/kg IV Q2W, respectively. Primary endpoints included overall response rate (ORR) using RECIST v1.1 and incidence/severity of adverse events. Key secondary endpoints included PK parameters, disease control rate (DCR), progression free survival (PFS) and overall survival (OS). Results As of 31-Oct-2023, 35 patients with stage IV biliary tract cancer (34 cholangiocarcinoma, 1 gallbladder adenocarcinoma) received S095018 in combination with Sym021. All patients were naïve to prior immune checkpoint inhibitor treatment. Twenty-two patients (62.9%) had received 1 prior antineoplastic systemic treatment for advanced/metastatic disease, 34.3% had received ≥2 prior treatments for advanced/metastatic disease. Overall, 34 patients (97.1%) discontinued treatment, 85.7% due to disease progression. Best overall response was 2 PR (5.7%), 11 SD (31.4%), 18 PD (51.4%) and 4 not evaluable. Median PFS and OS were 1.9 months (90% CI 1.8-3.7) and 13.4 months (90% CI 8.2-27.1) respectively. Disease control rate (CR+PR+SD) with SD≥16 weeks, ≥24 weeks and ≥12 months was 28.6%, 22.9% and 8.6% respectively. Treatment emergent adverse events of any grade occurring in >5% of patients included fatigue, pruritus, alkaline phosphatase increase, amylase increase, IRR (each 8.6%) and hypothyroidism, hyperthyroidism, AST increase, lipase increase and myalgia (each 5.7%). Exploratory biomarker analyses in paired tumor biopsies (N=18) showed an intratumoral increase in CD8 T-cell density, as well as upregulation of gene signatures related to IFNg signaling, antigen presentation, T-cell activation and cytotoxicity upon treatment. Baseline tumor biopsies from the two patients who achieved confirmed PR showed high PD-L1 expression. Conclusions: S095018 in combination with Sym021 exhibited antitumor activity in patients with advanced/metastatic recurrent biliary tract cancer who had not received prior treatment with PD-1/-L1 inhibitors. The combination was well tolerated without new safety signals. Further biomarker analysis is ongoing. Citation Format: Francois Ghiringhelli, Richard Kim, Teresa Macarulla, Irene Moreno, Albiruni Razak, Jordi Rodon, Chih-Yi Liao, Thomas Marron, Judith Raimbourg, Helene Kaplon, Julia Geromini, Najah Harouki, Christelle Rodrigues, Pauline Darcel, Niels Jorgen Skartved, Rikke Hald, Daleen Lopez-Ravnborg, Peng He, Xenophon Ianopoulos, Vasileios Askoxylakis, Nehal J. Lakhani, Sarah Davis, Amit Mahipal. A phase 1b multicenter study of anti-TIM3 (S095018/Sym023) in combination with anti-PD1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT133.
Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation
Atallah‐Yunes, Suheil Albert , Khurana, Arushi , Atallah-Yunes, Albert , Habermann, Thomas M.

Mayo Clinic

British Journal of Haematology | April 5, 2024 | Volume: 204 | Issue: 6 | Pages: 2165-2172

10.1111/bjh.19425 | PMID 38577716 Get It

SummaryMultiagent chemoimmunotherapy remains the standard of care treatment for Burkitt lymphoma leading to a cure in the majority of cases. However, frontline treatment regimens are associated with a significant risk of treatment related toxicity especially in elderly and immunocompromised patients. Additionally, prognosis remains dismal in refractory/relapsed Burkitt lymphoma. Thus, novel therapies are required to not only improve outcomes in relapsed/refractory Burkitt lymphoma but also minimize frontline treatment related toxicities. Recurrent genomic changes and signalling pathway alterations that have been implicated in the Burkitt lymphomagenesis include cell cycle dysregulation, cell proliferation, inhibition of apoptosis, epigenetic dysregulation and tonic B‐cell receptor‐phosphatidylinositol 3‐kinase (BCR‐PI3K) signalling. Here, we will discuss novel targeted therapy approaches using small molecule inhibitors that could pave the way to the future treatment landscape based on the understanding of recurrent genomic changes and signalling pathway alterations in the lymphomagenesis of adult Burkitt lymphoma.
Design and Development of a Powered Myoelectric Elbow Orthosis for Neuromuscular Injuries
Vignola, Claudio, Bhat, Sandesh G. , Hollander, Kevin W., Kane, Paul H., Miller, Emily J. , Martin, W. Brandon , Shin, Alexander Y. , Sugar, Thomas G. , Kane, Paul, Miller, Emily , Kaufman, Kenton R , Shin, Alexander Y , Bhat, Sandesh G , Kaufman, Kenton R.

Mayo Clinic

Military Medicine | April 3, 2024 | Volume: 189 | Issue: Supplement_3 | Pages: 585-591

10.1093/milmed/usae196 | PMID 39160856 Get It

ABSTRACT Introduction Recovering from neuromuscular injuries or conditions can be a challenging journey that involves complex surgeries and extensive physical rehabilitation. During this process, individuals often rely on orthotic devices to support and enable movement of the affected limb. However, users have criticized current commercially available powered orthotic devices for their bulky and heavy design. To address these limitations, we developed a novel powered myoelectric elbow orthosis. Materials and Methods The orthosis incorporates 3 mechanisms: a solenoid brake, a Bowden cable-powered constant torque elbow mechanism, and an extension limiter. The device controller and battery are in a backpack to reduce the weight on the affected arm. We performed extensive calculations and testing to ensure that the orthosis could withstand at least 15 Nm of elbow torque. We developed a custom software effectively control the orthosis, enhancing its usability and functionality. A certified orthotist fitted a subject who had undergone a gracilis free functioning muscle transfer surgery with the device. We studied the subject under Mayo clinic IRB no. 20-006849 and obtained objective measurements to assess the orthosis’s impact on upper extremity functionality during daily activities. Results The results are promising since the orthosis significantly improved elbow flexion range of motion by 40° and reduced compensatory movements at the shoulder (humerothoracic joint) by 50°. Additionally, the subject was able to perform tasks which were not possible before, such as carrying a basket with weights, highlighting the enhanced functionality provided by the orthosis. Conclusion In brief, by addressing the limitations of existing devices, this novel powered myoelectric elbow orthosis offers individuals with neuromuscular injuries/conditions improved quality of life. Further research will expand the patient population and control mechanisms.
Social relationships, amyloid burden, and dementia: The ARIC‐PET study
Groechel, Renée C. , Liu, Albert C. , Koton, Silvia , Kucharska‐Newton, Anna , Lutsey, Pamela L. , Palta, Priya, Sharrett, A. Richey , Wong, Dean F. , Lutsey, Pamela L , Kucharska-Newton, Anna M , Liu, Chelsea , Knopman, David S. , Mosley, Thomas H. , Walker, Keenan A. , Gottesman, Rebecca F.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | April 3, 2024 | Volume: 16 | Issue: 2 | Pages: No page available

10.1002/dad2.12560 | PMID 38571965 Get It

AbstractINTRODUCTIONThis study aimed to assess whether social relationships in mid‐life reduce the risk of dementia related to amyloid burden.METHODSParticipants in the Atherosclerosis Risk in Communities (ARIC) study were assessed for social support and isolation (visit 2; 1990–1992). A composite measure, “social relationships,” was generated. Brain amyloid was evaluated with florbetapir positron emission tomography (PET); (visit 5; 2012–2014). Incident dementia cases were identified following visit 5 through 2019 using ongoing surveillance. Relative contributions of mid‐life social relationships and elevated brain amyloid to incident dementia were evaluated with Cox regression models.RESULTSAmong 310 participants without dementia, strong mid‐life social relationships were associated independently with lower dementia risk. Elevated late‐life brain amyloid was associated with greater dementia risk.DISCUSSIONAlthough mid‐life social relationships did not moderate the relationship between amyloid burden and dementia, these findings affirm the importance of strong social relationships as a potentially protective factor against dementia.
Anticoagulation Patterns Among Community-Dwelling Older Adults With Atrial Fibrillation
Costello, Meaghan, Tung, Ericka E. , Jaeger, Thomas M. , Fischer, Karen M.

Mayo Clinic

Journal of Primary Care & Community Health | April 2, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241243005 | PMID 38561977 Get It

Objectives: To assess clinicians’ prescribing practices for anticoagulation in older adults with atrial fibrillation or atrial flutter (AF/F) and determine factors common among those without anticoagulation. Methods: We performed a community-based retrospective cohort study of adults aged 65 years and older with a history of nonvalvular AF/F to determine the rate of oral anticoagulation utilization. We also assessed for associations between anticoagulation use and comorbid conditions and common geriatric syndromes. Results: A total of 3832 patients with a diagnosis of nonvalvular AF/F were included (mean [SD] age, 79.9 [8.4] years), 2693 (70.3%) of whom were receiving anticoagulation (51.7%, a vitamin K antagonist; 48.1%, a direct-acting oral anticoagulant). Patients with higher Elderly Risk Assessment index (ERA) scores, a surrogate for health vulnerability, received anticoagulation less often than patients with lower scores. The percentage of patients with a history of falling was higher among those who did not receive anticoagulation than among those who did (44.4% vs 32.8%; P < .001). Similarly, a diagnosis of dementia was more common in the no-anticoagulation group than the anticoagulation group (18.5% vs 12.7%; P < .001). Conclusions: A substantial proportion of older adults with AF/F do not receive anticoagulation. Those without anticoagulation had higher risk of health deterioration based on higher ERA scores and had a higher incidence of dementia and fall history. This suggests that the presence of geriatric syndromes may influence the decision to withhold anticoagulation.
Improving Emergency Medicine Resident Pediatric Lumbar Puncture Procedural Performance through a Brief Just-In-Time Video Intervention
Finch, Alexander S. , Thomas, Jenna M., Lazaro, Octavio, Hevesi, Sara , Homme, Jim L.

Mayo Clinic

No container title available | April 1, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4152752/v1 Get It

Abstract BACKGROUND Emergency medicine (EM) trainee comfort level with lumbar puncture (LP) has decreased over time due to changing practice guidelines, particularly amongst pediatric patients. We implemented a “just in time” (JIT) brief educational video based on a validated LP evaluation checklist to improve trainee efficiency and competence in LP performance. METHODS Our experimental study took place January-June 2022 within a large, academic Midwestern emergency department (ED) with an established 3-year EM residency program. All 9 interns performed a timed diagnostic LP on an infant LP model in January, scored according to a previously validated LP Performance Scoring Checklist. In June, interns repeated the timed LP procedure directly after watching a brief educational video based on major checklist steps. The study was deemed exempt by the Institutional Review Board. RESULTS All interns completed both assessments. At baseline, interns had logged performance of median 2 (IQR 0–5) LPs and spent 12.9 (10.3–14.4) minutes performing the procedure. Post-intervention, interns had logged an additional median 2 (0–5) LPs and completed the procedure faster with an average time of 10.3 (9.7–11.3) minutes (p = 0.004). A median of 5 (4–7) major steps were missed at baseline, compared to 1 (1–2) at time of post-intervention assessment (p = 0.015). CONCLUSION Development of a brief educational video improved efficiency and competency amongst our intern class in performing an infant LP when viewed Just-In-Time. Similar efforts may improve education and performance of other rare (or decreasing in frequency) procedures within EM training. Future research with other procedures, larger learner cohorts, and comparing JIT approaches will be necessary to determine whether JIT videos based on validated assessment checklists are truly “best practice”. Formal evaluation of the effect of similar “standardized” videos on cognitive load of learners and supervisors is also an important avenue of future research.
The current state of training in pain medicine fellowships: An Association of Pain Program Directors ( APPD ) survey of program directors
Wahezi, Sayed , Caparó, Moorice , Choi, Heejung , Eshraghi, Yashar , Naeimi, Tahereh , Kohan, Lynn , Anițescu, Magdalena , Wright, Thelma , Przkora, Rene , Patel, Kiran V., Lamer, Tim J. , Moeschler, Susan M. , Yener, Ugur , Alerte, Jonathan, Grandhe, Radhika, Bautista, Alexander , Spektor, Boris , Noon, Kristen , Reddy, Rajiv , Osuagwu, Uzondu, Carpenter, A. Alden, Gerges, Frederic J., Murphy, Casey, Kim, Chong , Marshall, Cameron, Kirchen, Gwynne, Oryhan, Christine , Singh, Tejinder S. Swaran, Lubenow, Timothy R. , Sehgal, Nalini , Argoff, Charles E. , Gulati, Amit , Day, Miles, Sibai, Nabil, Dua, Anterpreet, Barad, Meredith , Singh, Tarun D. , Osuagwu, Uchechukwu Levi , Emerick, Trent D , Naeimi, Tahereh , Moeschler, Susan, Yener, Ugur , Bautista, Alexander , Reddy, Rajiv , Barad, Meredith J , Horn, Danielle Bodzin , Pritzlaff, Scott , Marshall, Cameron, Singh, Tejinder S. Swaran, Sayed, Dawood , Shaparin, Naum

Mayo Clinic

Pain Practice | March 30, 2024 | Volume: 24 | Issue: 7 | Pages: 895-903

10.1111/papr.13373 | PMID 38553945 Get It

Abstract Introduction The Accreditation Council for Graduate Medical Education (ACGME) approved the first pain medicine fellowship programs over three decades ago, designed around a pharmacological philosophy. Following that, there has been a rise in the transition of pain medicine education toward a multidisciplinary interventional model based on a tremendous surge of contemporaneous literature in these areas. This trend has created variability in clinical experience and education amongst accredited pain medicine programs with minimal literature evaluating the differences and commonalities in education and experience of different pain medicine fellowships through Program Director (PD) experiences. This study aims to gather insight from pain medicine fellowship program directors across the country to assess clinical and interventional training, providing valuable perspectives on the future of pain medicine education. Methods This study involved 56 PDs of ACGME‐accredited pain fellowship programs in the United States. The recruitment process included three phases: advanced notification, invitation, and follow‐up to maximize response rate. Participants completed a standard online questionnaire, covering various topics such as subcategory fields, online platforms for supplemental education, clinical experience, postgraduate practice success, and training adequacy. Results Surveys were completed by 39/56 (69%) standing members of the Association of Pain Program Directors (APPD). All PDs allowed fellows to participate in industry‐related and professional society‐related procedural workshops, with 59% encouraging these workshops. PDs emphasized the importance of integrity, professionalism, and diligence for long‐term success. Fifty‐four percent of PDs expressed the need for extension of fellowship training to avoid supplemental education by industry or pain/spine societies. Conclusion This study highlights the challenge of providing adequate training in all Pain Medicine subtopics within a 12‐month pain medicine fellowship. PDs suggest the need for additional training for fellows and discuss the importance of curriculum standardization.
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials
Gallois, Claire , Shi, Qian , Pederson, Levi , André, Thierry , Sobrero, Alberto F. , Alberts, Steven R. , Gramont, Aimery de , Meyerhardt, Jeffrey A. , George, Thomas J. , Souglakos, Ioannis , Harkin, Andrea , Shields, Anthony F. , Boukovinas, Ioannis , Goldberg, Richard M. , Papamichael, Demetris , Pederson, Levi D , Iveson, Timothy J , Sobrero, Alberto , Alberts, Steven R , De Gramont, Aimery , Meyerhardt, Jeffrey A , George, Thomas J , Schmoll, Hans-Joachim , Harkin, Andrea , Sinicrope, Frank A , Oki, Eiji , Shields, Anthony F , Boukovinas, Ioannis , Lonardi, Sara , Yothers, Greg , Yoshino, Takayuki , Goldberg, Richard M , Taieb, Julien , Papamichael, Demetris , André, Thierry , Shi, Qian , Iveson, Timothy , Schmoll, Hans‐Joachim , Labianca, Roberto , Sinicrope, Frank A. , Oki, Eiji , Kerr, Rachel , Lonardi, Sara , Yothers, Greg , Yoshino, Takayuki , Taı̈eb, Julien

Mayo Clinic

Journal of Clinical Oncology | March 28, 2024 | Volume: 42 | Issue: 19 | Pages: 2295-2305

10.1200/jco.23.01326 | PMID 38547438 Get It

PURPOSE A number of studies suggest that older patients may have reduced or no benefit from the addition of oxaliplatin to fluoropyrimidines as adjuvant chemotherapy for stage III colon cancer (CC). MATERIALS AND METHODS We studied the prognostic impact of age, as well as treatment adherence/toxicity patterns according to age, in patients with stage III CC who received 3 or 6 months of infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (CAPOX) on the basis of data collected from trials from the ACCENT and IDEA databases. Associations between age and time to recurrence (TTR), disease-free survival (DFS), overall survival (OS), survival after recurrence (SAR), and cancer-specific survival (CSS) were assessed by a Cox model or a competing risk model, stratified by studies and adjusted for sex, performance status, T and N stage, and year of enrollment. RESULTS A total of 17,909 patients were included; 24% of patients were age older than 70 years (n = 4,340). Patients age ≥70 years had higher rates of early treatment discontinuation. Rates of grade ≥3 adverse events were similar between those older and younger than 70 years, except for diarrhea and neutropenia that were more frequent in older patients treated with CAPOX (14.2% v 11.2%; P = .01 and 12.1% v 9.6%; P = .04, respectively). In multivariable analysis, TTR was not significantly different between patients <70 years and those ≥70 years, but DFS, OS, SAR, and CSS were significantly shorter in those patients ≥70 years. CONCLUSION In patients ≥70 years with stage III CC fit enough to be enrolled in clinical trials, oxaliplatin-based adjuvant chemotherapy was well tolerated and led to similar TTR compared with younger patients, suggesting similar efficacy. TTR may be a more appropriate end point for efficacy in this patient population.